Anna Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Lo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anna Marie Pyle
Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, USA
1 shared publication - Danielle M. Burgenske
Mayo Clinic, Rochester
1 shared publication - Eric D. Huseman
Department of Chemistry
1 shared publication - Fabian S. Menges
Department of Chemistry
1 shared publication - James Elia
Yale School of Medicine
1 shared publication - Jann Nagina Sarkaria
Mayo Clinic, Rochester, USA
1 shared publication
Latest Publications
- Open Access
- 13 June 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Glioblastoma (GBM) is a lethal brain cancer with a five-year survival rate of 10-fold more slowly from O6FEtG than O6ClEtG, and this slower rate of cross-linking allows MGMT to reverse the initial O6FEtG in healthy tissue while also reducing MGMT–DNA cross-links arising from addition of MGMT to the N1,O6EtG intermediate. KL- 50 is efficacious in an intracranial patient-derived murine xenograft of TMZ-resistant, MGMT–/MMR– GBM (mOS = 205, 28, and 26 d for KL-50, TMZ, and vehicle-treated control, respectively) and in murine models of newly-diagnosed MGMT–/MMR+ GBM, suggesting its use in recurrent and up-front settings, respectively. These studies underscore the significance of considering the rates of chemical DNA modification and biochemical DNA repair in the design of systemic DNA alkylation agents.
- 13 June 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Glioblastoma (GBM) is a lethal brain cancer with a five-year survival rate of 10-fold more slowly from O6FEtG than O6ClEtG, and this slower rate of cross-linking allows MGMT to reverse the initial O6FEtG in healthy tissue while also reducing MGMT–DNA cross-links arising from addition of MGMT to the N1,O6EtG intermediate. KL- 50 is efficacious in an intracranial patient-derived murine xenograft of TMZ-resistant, MGMT–/MMR– GBM (mOS = 205, 28, and 26 d for KL-50, TMZ, and vehicle-treated control, respectively) and in murine models of newly-diagnosed MGMT–/MMR+ GBM, suggesting its use in recurrent and up-front settings, respectively. These studies underscore the significance of considering the rates of chemical DNA modification and biochemical DNA repair in the design of systemic DNA alkylation agents.